| abstract |
Embodiments of the present disclosure include methods of treating myasthenia gravis, including generalized myasthenia gravis, by providing C5 complement inhibitors. Included are devices and kits for inhibitor administration and methods of evaluating complement inhibitor treatment efficacy. |